Daiichi Sankyo positions Asubio as discovery operation
This article was originally published in Scrip
Executive Summary
Daiichi Sankyo is to restructure its Asubio Pharma subsidiary next year, turning it into a more tightly focused drug discovery operation in order to strengthen its in-house research.